research as Yale-Pfizer Visiting Fellow
Agnès Vignery, associate professor of orthopaedics and rehabilitation and of cell biology has been named Yale-Pfizer Global Discovery Visiting Professor for 2005.
Vignery's research focuses on the developmental and reconstructive processes of bone. At Pfizer's Groton Laboratories, she will serve as a consultant to David Ke in the bone biology section and John Cheng in the biomarkers group. She will conduct collaborative research and gain practical knowledge of the drug discovery and development process through interactions with the project teams.
The program offers a 12-week position for one outstanding Yale faculty member to consult and do research on site at Pfizer Global Research and Development in Groton/New London. It strengthens Yale-Pfizer alliances by University faculty with new collaborations and a better understanding of the pharmaceutical industry.
"We are pleased that the Pfizer Visiting Professor Program is proving to be such a successful partnership," says Merle Waxman, associate dean and director of the Office for Women in Medicine at Yale School of Medicine. "Our scientists gain great first-hand experience in the challenges of the pharmaceutical industry and then have the unique opportunity to bring these insights back to their students and fellows."
The novel visiting professorship, now in its second year, was developed and sponsored by the Discovery Laboratories at Pfizer Global Research and Development, the Women's Leadership Network at Pfizer and the Office for Women in Medicine at Yale.
"This is an honor that has given me the opportunity to work with a premier pharmaceutical company on research that is not only important to me, but important to improving health care in the United States," says Vignery.
Vignery's lab recently developed a new technology to induce bone formation locally for the prevention of fractures and the repair of non-union fractures. The technology is being refined in rodents, anticipating its rapid translation to humans.
"One vision for the program is to enhance the scientific understanding between Pfizer and Yale, and, more broadly, between industry and academia. We have already seen how beneficial these interactions can be," says Karen Houseknecht, president of the Women's Leadership Network at Pfizer. "We look forward to this program expanding the vista of career choices for academic scientists."
T H I S
W E E K ' SS T O R I E S
School of Music receives gift of $100 million
Class of 1954 Chemistry Building officially opened
IOM elects six from Yale
Yale will mark Veterans Day with salute to alumnus, flag rededication
University dedicates new Rudd Center for Food Policy & Obesity
World Fellow Ibrahim honored for her human rights work in Nigeria
Today's press fails to get 'to the bottom of things,' journalist says
Activist calls for cohesive global response to international migration
Yale's matching gift to United Way supports school readiness
Wife's illness inspires pathologist to investigate Alzheimer's
Yale employee lends skills to help animals after the hurricane
Doctor's career spent researching body's 'master chemical director'
MEDICAL CENTER NEWS
Researchers find strong link between gene and dyslexia
Study casts light on nature and spread of lethal brain diseaes
Innovative therapy curbs effects of loss of oxygen during birth
Study finds true reason that lymph nodes swell
Helping breast cancer patients find best online information . . .
Merson speaks at launch of Russia's first M.P.H. program
New Yorker humorist to give public reading
Veterans Day concert will feature School of Music alumni
Alumni innovators to discuss 'Entrepreneurship and the Law'
Vignery to conduct pharmaceutical research as Yale-Pfizer Visiting Fellow
Cell biologist Ira Mellman elected to prestigious EMBO
Richard Lalli to perform at benefit gala for the Neighborhood Music School
Bulletin Home|Visiting on Campus|Calendar of Events|In the News
Bulletin Board|Classified Ads|Search Archives|Deadlines
Bulletin Staff|Public Affairs|News Releases|
E-Mail Us|Yale Home